Mylan's stance on certain generic drugs has changed significantly over the past decade, with the company put in a similar position now to one its CEO lambasted 10 years ago. Mylan CEO Heather ...

Mylan’s CEO, Heather Bresch, has been forced to defend the pricing of its EpiPen under sceptical questioning from US politicians. Bresch (pictured) was summoned to a hearing in front of the ...

To make things more complicated, Mylan's CEO Heather Bresch is the daughter of Senator Joe Manchin of West Virginia. Bloomberg caught up with the senator Tuesday to discuss his daughter and the ...

Well, that was fast. It took Gov. Jim Justice all of one day after winning a seat in the U.S. Senate to play an exclusive game of political nepotism, appointing his wife, Cathy, to a nine-year term on ...

Heather Bresch, CEO of pharmaceutical company Mylan, appeared before the US government’s House Oversight and Government Reform Committee two weeks ago. In a hearing over the price of her company ...

Zero. Congress’s sole contribution to the existence of a handy device that keeps your children from dying from bee stings is the fact that Mylan CEO Heather Bresch is the daughter of a ...

Mylan CEO Heather Bresch has drawn public scrutiny for raising the US list price on a pack of two injectors nearly six-fold to $600 since 2008. Affordability has become a bigger issue with the ...

Mylan President Rajiv Malik and Emcure Pharmaceuticals CEO Satish Mehta are both named as defendants to the 243-page complaint, which was transferred from Connecticut to Philadelphia. Led by ...

After Viatris’ CEO earlier this year promised to be “opportunistic ... Amid GLP-1 craze, Novo and Mylan ink patent settlement in Ozempic case After a long and tortuous path to approval ...

Gilead's collaboration with pharmaceutical firms across the globe, also including Eva Pharma, Ferozsons Laboratories Limited, ...

CEO Scott Smith's “Phase 2” strategy focuses ... inherited from Pfizer / Mylan. The company earned ~$1.3bn in Europe in Q2, ~$1bn in the US, ~$580m in emerging markets, $350m in Japan ...